


Repackaging Beyond-Use Date (BUD) Decision Workflow
(Revised for 2023 USP <795> and <797> chapter versions)



Decision Workflow References (indicated in parentheses above)

1. USP General Chapter <795> Pharmaceutical Compounding-Nonsterile Preparations (official 11/1/23)
2. USP General Chapter <797> Pharmaceutical Compounding-Sterile Preparations (official 11/1/23)
3. USP General Chapter <1178> GOOD REPACKAGING PRACTICES (updated December 2020)
4. USP General Chapter <7> Labeling (Official May 2020)
5. FDA. Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities: Guidance. (Jan 2017, <https://www.fda.gov/media/90978/download>)
6. FDA. Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance. (June 2016, <https://www.fda.gov/media/94393/download>).

* Unless stability data or the manufacturer's labeling indicates a shorter BUD

- Category 1 CSPs (SCA):** compounding area
- Room Temp: 12 hours
 - Fridge: 24 hours
- Category 2 CSPs (cleanroom):** Aseptically processed CSPs prepared from sterile components without Sterility Testing.
- Room Temp 4 days
 - Fridge: 10 days
 - Frozen: 45 days
- Category 3 CSPs:** Additional testing requirements exist.

Created by Jamie Tharp
Reviewed by Shannon Buxell, Renee Douglass, Jeff Pilz, and Kayleigh Thompson
October 2024

Repackaging Assumptions:

Repackaging BUD assigned within the institution will not conflict with manufacturer's approved labeling.

The above branches represent maximum allowed BUDs; institutions may choose more conservative BUDs based internal factors and preference. See ASHP's Pharmacist Guide to Assigning a BUD [link here]

Manufacturer product labeling dating may exceed USP <795> or <797> BUD requirements, provided product is prepared as single dose for single patient and approved labeling has all required information(2,5)